Cancer-associated heterogeneous ribosome

Cancer-associated heterogeneous ribosomes, also known as onco-ribosomes, represent a specialized class of protein-synthesis machinery characterized by distinct ribosomal protein compositions or ribosomal RNA (rRNA) modifications (Barna et al., 2022, Nature Reviews Cancer). Unlike the traditional view of ribosomes as invariant, these heterogeneous populations allow cancer cells to selectively translate specific subsets of mRNAs that drive malignancy, such as those involved in the epithelial-mesenchymal transition (EMT), metastasis, and cell survival (Pelletier et al., 2018, Nature). This selective translation provides a mechanism for tumor cells to adapt to environmental stressors and maintain a proliferative state (Genuth & Barna, 2018, Nature Reviews Molecular Cell Biology). Therapeutic targeting of these ribosomes often involves the inhibition of RNA polymerase I to disrupt rRNA synthesis or the targeting of specific rRNA-modifying enzymes like fibrillarin (Drygin et al., 2011, Cancer Research). Small molecules such as CX-5461 are currently being evaluated in clinical trials for their ability to induce nucleolar stress and p53-dependent apoptosis by interfering with the assembly of these specialized ribosomes (Khanna et al., 2018, JCI Insight). Understanding the unique landscape of onco-ribosomes offers a promising avenue for developing precision therapies that spare normal cells while crippling the translational program of the tumor (Marcel et al., 2013, Cancer Cell).

Other names

Onco-ribosomeSpecialized ribosomeHeterogeneous ribosomeCancer ribosomeSpecialized translation machinery

Inhibition of RNA polymerase I-mediated transcription of ribosomal DNA, disruption of ribosome biogenesis, and selective inhibition of the translation of oncogenic mRNAs.